Jing Li
Founder & Chief Executive Officer VelaVigo
Experienced Senior Executive with a demonstrated history of working in the pharmaceuticals industry. Well-established track records of achievement in drug discovery, technology development, and company financials. Skilled in Biotechnology, Life Sciences, Technology Development, Drug Discovery and Development, and Team Management. Strong professional graduated from Peking University and Yale University.
Seminars
Thursday 26th March 2026
The Trispecific TCE or Bispecific ADC: A New Way to Deeply Deplete B-Cells Potentially for Oncology & Autoimmune Diseases
9:00 am
- Examine the potential of trispecific T-cell engagers TCEs and bispecific ADCs as next-generation strategies for deep B-cell depletion across oncology and autoimmune indications
- Understand the mechanistic advantages of multi-specific modalities in enhancing precision, potency, and durability compared to traditional approaches
- Explore translational insights and early data shaping the clinical promise of these innovative platforms for redefining treatment paradigms
